[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599339":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":33,"collaborators":7,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Ahn-Gook Pharmaceuticals Co.,Ltd","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Deok Kyu Cho","Severance Hospital","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Hyunji Kim","CONTACT","+82-2-3289-4215","hyunji.kim@ahn-gook.com",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":7,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Yongin Severance Hospital","RECRUITING","Yongin-si","South Korea",{"type":26,"coordinates":27},"Point",[28,29],127.08042,37.29686,{"lat":29,"lon":28},[32],{"name":10,"role":16,"phone":7,"phoneExt":7,"email":7},{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100599339","a-study-to-evaluate-the-effectiveness-and-safety-of-fixed-dose-combination-of-pitavastatin-ezetimibe-100599339",false,"NCT07083206","A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin\u002F Ezetimibe","A Multi-center, Prospective, Non-intervention, Observational Study to Evaluate the Effectiveness and Safety of Switching to Pevarozet Tablet in Patients With Hypercholesterolemia Previously Treated With Atorvastatin or Rosuvastatin Monotherapy","PIVOTAL","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Patients diagnosed with hypercholesterolemia who have been stably treated with atorvastatin or rosuvastatin monotherapy for at least 3 months, and for whom switching to fixed-dose combination pitavastatin\u002Fezetimibe has been clinically decided\n* Patients with available clinical laboratory test results related to efficacy and safety (TC, TG, HDL-C, LDL-C, AST, ALT, Cr\u002FeGFR) within 12 months prior to switching to fixed-dose combination pitavastatin\u002Fezetimibe (no changes in statin regimen or dosage during that period)\n* Individuals (or their legally authorized representatives) who voluntarily provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Known hypersensitivity or history of hypersensitivity to any component of the investigational product\n* Patients with active liver disease or persistent, unexplained elevations of aminotransferase levels\n* Patients with severe hepatic impairment, biliary obstruction, or cholestasis\n* Patients currently receiving cyclosporine treatment\n* Patients diagnosed with myopathy\n* Pregnant or breastfeeding women, or women who may be pregnant\n* Patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n* Any patient who, in the opinion of the investigator, is deemed unsuitable for study participation","ALL","19 Years",{"count":46,"type":47},4500,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate the effectiveness and safety of Pitavastatin\u002FEzetimibe FDC in patients with hypercholesterolemia.",[51,52],"Hypercholesterolemia","Dyslipidemias","2025-08-03",{"date":55,"type":56},"2025-08-07","ACTUAL",{"date":58,"type":56},"2025-07-29",{"date":60,"type":47},"2029-01",{"name":5,"class":6},1]